EHA 2023 | HOVON 141/VISION trial update: MRD-guided venetoclax + ibrutinib treatment for R/R CLL

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, provides an update on the follow-up data from the randomized Phase II HOVON-141/VISION trial (NCT03226301) evaluating venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). In this trial, patients who achieved undetectable measurable residual disease (MRD) after 15 cycles of treatment were randomized to ibrutinib maintenance or observation with MRD testing every three months. The trial showed that treatment discontinuation based on MRD testing is feasible. In addition, the study also showed that it is possible to retreat patients with the venetoclax-ibrutinib combination upon molecular relapse. The adverse event burden was higher in the ibrutinib maintenance arm than in the observation arm. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.